Identification of a 5-gene signature panel for the prediction of prostate cancer progression
Menée à partir de l'analyse protéomique d'échantillons tissulaires prélevés lors de l'autopsie d'hommes atteints d'un cancer métastatique ou localisé de la prostate puis à l'aide d'une série de données cliniques, cette étude identifie une signature, basée sur l'expression d'un panel de 5 gènes (U2AF2, RUVBL1, STMN1, HDGF et FABP4), pour prédire la progression tumorale
Background : Despite nearly 100% 5-year survival for localised prostate cancer, the survival rate for metastatic prostate cancer significantly declines to 32%. Thus, it is crucial to identify molecular indicators that reflect the progression from localised disease to metastatic prostate cancer.
Methods : To search for molecular indicators associated with prostate cancer metastasis, we performed proteomic analysis of rapid autopsy tissue samples from metastatic prostate cancer (N = 8) and localised prostate cancer (N = 2). Then, we utilised multiple independent, publicly available prostate cancer patient datasets to select candidates that also correlate with worse prostate cancer clinical prognosis.
Results : We identified 154 proteins with increased expressions in metastases relative to localised prostate cancer through proteomic analysis. From the subset of these candidates that correlate with prostate cancer recurrence (N = 28) and shorter disease-free survival (N = 37), we identified a 5-gene signature panel with improved performance in predicting worse clinical prognosis relative to individual candidates.
Conclusions : Our study presents a new 5-gene signature panel that is associated with worse clinical prognosis and is elevated in prostate cancer metastasis on both protein and mRNA levels. Our 5-gene signature panel represents a potential modality for the prediction of prostate cancer progression towards the onset of metastasis.
British Journal of Cancer , article en libre accès, 2024